IGC Pharma, Inc. (IGC)

[NetworkNewsWire]

IGC Releases Results of Annual Shareholders Meeting

India Globalization Capital, Inc. (NYSE American: IGC) yesterday announced that during its 2016-2017 Annual Meeting of Shareholders on November 8, 2017, voting on Proposals Three and Four was adjourned to November 22, 2017 at 11:00 a.m. EST due to the lack of required stockholders needed. Stockholders of record on October 5, 2017 are eligible and requested by IGC to vote on these proposals that are available in the company’s proxy statement filed with the Securities and Exchange Commission (http://nnw.fm/6yMe4). Eligible stockholders may vote at www.ProxyVote.com, by dialing 800-454-8683, or by returning a properly executed proxy card to InvestorCom. The following proposals were approved at the annual meeting: (1) the election of Sudhakar Shenoy and Ram Mukunda as directors, (2) the proposal to ratify AJSH & Company as the company’s independent registered public accounting firm for the 2018 fiscal year, (3) the adoption of the company’s 2018 Omnibus Incentive Plan, (4) a non-binding advisory resolution to approve the compensation of the company’s named executive officers, and (5) approval to adjourn the meeting.

To view the full press release, visit http://nnw.fm/t02bS

About IGC

IGC is engaged in the development of cannabis based combination therapies to treat Alzheimer’s, pain, nausea, eating disorders, several end points of Parkinson’s, and epilepsy in dogs and cats. IGC has assembled a portfolio of patent filings and four lead product candidates addressing these conditions. The company is based in Maryland, USA. For more information please visit www.IGCinc.us.